Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Supply chain

Drug wholesalers discuss contingency plans with government to prepare for 'no-deal' Brexit

The Healthcare Distribution Association has said current preparations to build up buffer stocks in case of a ‘no-deal’ Brexit scenario mirror those of a flu pandemic.

Martin Sawer, executive director at the Healthcare Distribution Authority

Source: Courtesy, Healthcare Distribution Association

It is likely that wholesalers will request extra stock from pre-wholesalers in the early months of 2019, before the UK leaves the EU on 29 March 2019, Martin Sawer has said

The Healthcare Distribution Association (HDA), which represents drug wholesalers and distributors, has already met with the Department of Health and Social Care (DHSC) to discuss contingency measures in the event of a “no-deal” Brexit, its executive director has told The Pharmaceutical Journal.

“We are talking to the government to try and assess what the preparedness state is at the moment [in the event of a no deal],” Martin Sawer, executive director at the HDA, has said.

“It’s about understanding the capacity of the UK market and building up a buffer stock should there be a no-deal scenario. Communication is going to be key.”

Sawer said that the current discussions and moves being suggested mirror those which would traditionally happen in anticipation of a pandemic flu outbreak, or the steps that were taken across the sector around potential medicine demand before the Olympic Games in London in 2012.

He said it is likely that wholesalers will request extra stock from their pre-wholesaler suppliers from January 2019 until March 2019, when the UK is scheduled to depart the EU.

“The other role we have is to talk to the pre-wholesalers, who supply wholesalers, to ‘sensitise’ them to our demands and quantities of medicines that we need, so that there aren’t any gaps [in the supply chain],” he said.

Sawer was unable to predict which specific extra drug stock might be needed and expected that decision would be down to the DHSC. 

“Each medicine will be looked at in terms of its route and how it will get to pharmacies — the devil will be in the detail.

“The government is doing the best that it can and it would be irresponsible if it was not doing any planning in the event of a no deal.

“One person not getting their critical medicine if there is no deal is one person too many.”

On 24 July 2018, health and social care secretary Matt Hancock told a meeting of the House of Commons health select committee that he had asked civil servants to “accelerate” plans, including preparation for the potential need for stockpiling of drugs, to deal with the consequences of the UK leaving the EU in 2019 with no agreement in place.

President of the Royal Pharmaceutical Society (RPS), Ash Soni, said that the risk of the Brexit resulting in delays in patients accessing medicines was a concern widely recognised across the healthcare sector.

“With some medicines manufacturers now talking about contingency plans to stockpile medicines in the absence of a negotiated deal, we are engaging with regulators and the NHS about their plans to minimise any potential disruption to the medicines supply chain.

“It’s understandable that current uncertainties about Brexit are raising concerns about patient care. Ultimately, I’m confident that pharmacists will continue to ensure that patient safety remains their top priority, and that the RPS will be on hand to help the profession manage future changes.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205242

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • Prescribing Medicines for Children

    Prescribing Medicines for Children

    Prescribing Medicines for Children is designed to improve understanding on all aspects of paediatric prescribing, from the development of suitable drugs through to their practical administration.

    £60.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Martin Sawer, executive director at the Healthcare Distribution Association

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.